The reduction in binding to the SNV variant in in vitro binding assays was almost equal to a reduction in promotor activity in reporter gene assays, which strongly suggests that PARP-1 is a critical component for the full induction of the breast cancer-associated promoter I.3/II-region. The gene discussed is PARP1; the disease is breast cancer.